Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)

American Journal of Obstetrics and Gynecology

Volumn 205, Issue 6, 2011, Pages 535.e1-535.e5

  Runowicz, Carolyn D ^a,d   Costantino, Joseph P ^a,b   Wickerham, D Lawrence ^a,c   Cecchini, Reena S ^a,b   Cronin, Walter M ^a,b   Ford, Leslie G ^a,e   Vogel, Victor G ^a,f   Wolmark, Norman ^a,c  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f GEISINGER HEALTH SYSTEM   (United States)

Author keywords

breast cancer prevention; gynecologic condition; raloxifene; tamoxifen

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; LEIOMYOMA; MAJOR CLINICAL STUDY; OVARY CYST; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; UTERUS CANCER; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS;

EID: 81855166887     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2011.06.067     Document Type: Article

References (8)

1. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388 (Pubitemid 28439961)
2. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: Multiple Outcomes of Raloxifene Evaluation JAMA 281 1999 2189 2197 (Pubitemid 29275701)
3. S. Martino, J.A. Cauley, and E. Barrett-Connor Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 2004 1751 1761 (Pubitemid 39654569)
4. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
5. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer Cancer Prev Res 3 2010 696 706
6. J.P. Costantino, M.H. Gail, and D. Pee Validation studies for models to project the risk of invasive and total breast cancer incidence J Natl Cancer Inst 91 1999 1541 1548 (Pubitemid 29457958)
7. E. Chalas, J.P. Costantino, and D.L. Wickerham Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial Am J Obstet Gynecol 192 2005 1230 1239 (Pubitemid 40487803)
8. J.G. Williamson, and J.D. Ellis The induction of ovulation by tamoxifen J Obstet Gynaecol Br Cmnwlth 80 1973 844 847